The U.S. Food and Drug Administration has approved a biotech vaccine called the Bioengineered Vaccine (BGV) as a vaccine to treat autism and Duchenne muscular dystrophy, the Associated Press reported.
The vaccine will be administered to people who have not been vaccinated with any of the seven existing vaccines that have been tested.
It has been developed by a group of biotech firms called Illumina Inc., Sanofi Pasteur S.A., and AbbVie Inc. The first-of-its-kind vaccine is being tested in California and a trial is being conducted in Connecticut.
It is being developed as a biologic, or bioengineered, vaccine and it has been engineered to be able to deliver the same powerful immune response to the body as the existing vaccines.
“This is a very promising technology and I believe it has tremendous potential for being able to provide a vaccine that is safe, effective and affordable,” said John O’Donnell, chairman of the advisory board of the American Academy of Pediatrics, in a statement.
The FDA approved the BGV in October 2015, just three months after a new generation of vaccine candidate viruses was published in the journal Science.
Researchers said that the vaccine can be administered by injection or through the skin.
The vaccines will be tested on a small group of people who will be selected at random, according to the AP.
The drug company has previously raised money to develop the vaccine.
“We will continue to invest in this important development, and the future of this important vaccine will depend on continued strong regulatory approvals and a successful trial,” said Abbvie spokeswoman Anna De Vanna.
“In addition to being the first vaccine candidate vaccine candidate that will have been approved by the FDA, the BioEngineered vaccine will also be one of the first products to be licensed by the U.K. government to the American public,” she added.
The BGV vaccine is the first of several vaccines being tested.
and U.N. have approved several vaccine candidates for use in the treatment of autism and the Duchennes disease.
The other three are a vaccine for HIV and hepatitis B, and a vaccine called Merck’s SIViN, which is being designed for children with Crohn’s disease and Crohn-related reflux disease.
In May, the U and European Medicines Agency approved a third vaccine, known as SARS-CoV-2, that is designed to help people who contracted SARS in the Middle East.
The new vaccine will allow people to be vaccinated without having to have the virus in their blood or in their lungs, and it is being administered to a small number of people in the U.-K., in a trial in the United Kingdom.
A study last year by researchers at Imperial College London showed that the SIViiN vaccine was 100% effective in helping people who were infected with SARS to be protected from the virus.
But there are other vaccines that could be used in the future, including one for Hepatitis C, the other for Duchennes disease, and an influenza vaccine.
The approval by the US Food and Human Services agency of the BGEV is not the first time that vaccines have been designed to target specific viruses.
A number of vaccines are being tested that target viruses like the Zika virus and the coronavirus.
Another vaccine is a vaccine designed to protect against polio, which has spread around the world and caused more than 1.1 million deaths in the past two years.